Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
123M
-
Number of holders
-
196
-
Total shares
-
122M
-
Shares change
-
+13.6M
-
Total reported value, excl. options
-
$2.1B
-
Value change
-
+$235M
-
Put/Call ratio
-
0.18
-
Number of buys
-
103
-
Number of sells
-
-75
-
Price
-
$17.18
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2019
211 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q2 2019.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 196 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 122M shares
of 123M outstanding shares and own 99.23% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (13.3M shares), BlackRock Inc. (12.6M shares), Third Security, LLC (10.7M shares), Bellevue Group AG (8.25M shares), Invesco Ltd. (5.39M shares), IRIDIAN ASSET MANAGEMENT LLC/CT (4.85M shares), JPMORGAN CHASE & CO (4.82M shares), STATE STREET CORP (4.43M shares), Thrivent Financial for Lutherans (3.79M shares), and PICTET ASSET MANAGEMENT LTD (3.71M shares).
This table shows the top 196 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.